LGG-46. TRAMETINIB THERAPY IN PEDIATRIC PATIENTS WITH LOW-GRADE GLIOMAS (LGG) WITH BRAF GENE FUSION; A DISEASE-SPECIFIC COHORT IN THE FIRST PEDIATRIC TESTING OF TRAMETINIB

BACKGROUND: LGG is the most prevalent childhood brain tumor. BRAF fusions drive constitutive activation of BRAF and tumorigenesis. We report results of trametinib, a MEK1/2 inhibitor, in pediatric patients with LGG with BRAF fusion. METHODS: This phase 1/2 trial (NCT02124772) enrolled pediatric pati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Bouffet, Eric, Kieran, Mark, Hargrave, Darren, Roberts, Stephen, Aerts, Isabelle, Broniscer, Alberto, Geoerger, Birgit, Dasgupta, Kohinoor, Tseng, Lillian, Russo, Mark, Mookerjee, Bijoyesh, Moertel, Christopher
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012791/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.387
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky